Adjuvant hormonal treatment for prostate cancer: The bicalutamide early prostate cancer program

Oncology

Volumn 65, Issue SUPPL. 1, 2003, Pages 1-4

  Wirth, Manfred P ^a   Froehner, Michael ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Adjuvant; Bicalutamide; Hormonal treatment; Prostate cancer; Radical prostatectomy; Radiotherapy; Watchful waiting

Indexed keywords

ANTIESTROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN DERIVATIVE; TAMOXIFEN;

ADVANCED CANCER; BEAM THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CAUSE OF DEATH; CLINICAL TRIAL; DISEASE COURSE; DRUG TOLERABILITY; FOLLOW UP; GYNECOMASTIA; HUMAN; LYMPH NODE DISSECTION; LYMPHADENOPATHY; MASTALGIA; MATURATION; META ANALYSIS; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SURVIVAL RATE; TREATMENT FAILURE; TUMOR GROWTH;

ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DISEASE PROGRESSION; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0041912998     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072484     Document Type: Review

References (24)

1. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152:1850-1857.
2. Gerber GS, Thisted RA, Chodak GW, Schröder FH, Frohmüller HG, Scardino PT, Paulson DF, Middleton AW, Rukstalis DB, Smith JA, Ohori M, Theiss M, Schellhammer PF: Results of radical prostatectomy in men with locally advanced prostate cancer: Multi-institutional pooled analysis. Eur Urol 1997;32:385-390.
3. Bolla M: Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer. Eur Urol 1999;35(suppl 1):23-26.
4. Barry MJ, Albertsen PC, Bagshaw MA, Blute ML, Cox R, Middleton RG, Gleason DF, Zincke H, Bergstralh EJ, Jacobsen SJ: Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: A retrospective analysis. Cancer 2001;91:2302-2314.
5. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D: Phase III trial of androgen suppression using goserelin in unfavourable prognosis carcinoma of the prostate treated with definitive radiotherapy - report of RTOG protocol 85-31. J Clin Oncol 1997;15:1013-1021.
6. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV: Updated results of the phase III radiation therapy oncology group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49:937-946.
7. Granfors T, Modig H, Damber JE, Tomic R: Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized study. J Urol 1998;159:2030-2034.
8. Arcangeli G, Saracino B, Micheli A, D'Angelo L, Pansadoro V, Cruciani E, Marchetti P: Radiotherapy with or without androgen deprivation in the treatment of localized adenocarcinoma of the prostate. Am J Clin Oncol 1998;21:1-5.
9. Hanks GE, Lu J, Machtay M, Venkatesan V, Pinover W, Byhardt R, Rosenthal SA: RTOG Protocol 92-02:A phase III trial of the use of long-term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate (abstract). Proc ASCO 2000;19:327a.
10. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002;360:103-106.
11. Zincke H, Bergstralh EJ, Larson-Keller JJ, Farrow GM, Myers RP, Lieber MM, Barrett DM, Rife CC, Gonchoroff NJ: Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Cancer 1992;70:311-323.
12. Seay TM, Blute ML, Zincke H: Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol 1998;159:357-364.
13. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999:341:1781-1788.
14. Prayer-Galetti T, Zattoni F, Capizzi A, Dal Moro F, Pagano F on behalf of the study group: Disease free survival in patients with pathological 'C stage' prostate cancer at radical retropubic prostatectomy submitted to adjuvant hormonal treatment (abstract). Eur Urol 2000;38(suppl 4):504.
15. Zincke H, Lau W, Bergstralh, Blute ML: Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 2001;166:2208-2215.
16. Wirth M, Frohmüller H, Marx F, for the study group: Adjuvant antiandrogenic treatment after radical prostatectomy in stage C prostate cancer - preliminary results of a randomized controlled multicenter trial (abstract). J Urol 1997;157(suppl):1308.
17. Wirth MP, Weissbach L, Marx FJ, Heckl W, Jellinghaus W, Riedmiller H, Noack B, Froehner M: Prospective randomised trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for stage pT3pN0 prostate cancer (abstract). J Urol 2003;169:343.
18. Nair B, Wilt T, MacDonald R, Rutks I: Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 2002;(1):CD003506.
19. Wirth MP, Froehner M: The value of endocrine therapy for early and locally advanced prostate cancer. Drugs Aging 2003;20:115-124.
20. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998;251:1451-1467.
21. Wirth M, Tyrrell C, Wallace M, Delaere KP, Sanchez-Chapado M, Ramon J, Hetherington J, Pina F, Heynes CF, Borchers TM, Morris T, Stone A: Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 2001;58:146-151.
22. See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ; Casodex Early Prostate Cancer Trialist Group: Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: First analysis of the early prostate cancer program. J Urol 2002;168:429-435.
23. See WA, McLeod D, Iversen P, Wirth M: The Bicalutamide Early Prostate Cancer Program. Demography. Urol Oncol 2001;6:43-47.
24. Wirth MP, Froehner M: Perspectives in adjuvant treatment of prostate cancer. Urol Int 2002;85:1-5.